pharma · AML/MDS · Hepatocellular Carcinoma (HCC) · SNTI
Essential Pharma
Essential Pharma Limited
Essential Pharma is a pharma organization headquartered in Egham, GB. It trades on NYSE under ticker SNTI. Primary therapeutic focus areas include AML/MDS, Hepatocellular Carcinoma (HCC). NovaPharmaNews links 2 clinical
Egham, GB HQ
2000 Founded
111 Employees
Public company Type
SNTI · NYSE Ticker
Company details
- Status
- Public
- HQ
- Egham, GB
- Founded
- 2000
- Employees
- 111
- Programs
- 2
- Drugs
- 3
- Patents
- 95
SN301A
Phase 1 · mab · Hepatocellular Carcinoma (HCC)
SN301A for Hepatocellular Carcinoma (HCC) is a Phase 1 program (mab) at Essential Pharma Limited with 1 ClinicalTrials.gov record(s).
Internal code SN301A-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Essential Pharma Limited
- Phase
- Phase 1
- Modality
- mab
- Indication
- Hepatocellular Carcinoma (HCC)
- Status
- active
- Trials
- 1